Gene Engineering in Stem Cells for Drug Discovery and Therapeutic

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Regenerative Engineering".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 3568

Special Issue Editor


E-Mail Website
Guest Editor
Center for Genomics and Proteomics, School of Medicine, Gachon University, Incheon 406-840, Republic of Korea
Interests: stem cell CRISPR editing; stem cell therapeutics; allogeneic manufacturing; CAR-T/NK cells; stem cell proteomics/genomics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Gene engineering technologies from viral vector-mediated to protein-based editing such as ZFN, TALENs, and CRISPR/Cas systems have been improved significantly. These technologies with stem cells have facilitated drug discovery and have resulted in the development of promising curative therapies for many intractable diseases. They can efficiently correct genetic errors; however, these technologies have limitations, such as off-target effects and possible safety issues, which need to be considered when employing these techniques in humans and animals. Significant efforts have been made to overcome these limitations and to accelerate the clinical implementation of these technologies.

In this way, the recent technological advancements in gene engineering and their applications in stem cells are developing to enable the efficient discovery of drugs and treatment of intractable diseases.

The main relevant topics for this Special Issue are:

  • Precise gene editing techniques
  • Safe and efficient therapeutics development
  • Application of gene engineering platform in drug discovery
  • Novel techniques in gene engineering
  • Preclinical and clinical studies, etc.

Prof. Dr. Bonghee Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • stem cells
  • gene editing
  • CRISPR-Cas
  • TALEN
  • drug discovery
  • therapeutics development

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 562 KiB  
Review
Therapeutic Applications of the CRISPR-Cas System
by Kyungmin Kang, Youngjae Song, Inho Kim and Tae-Jung Kim
Bioengineering 2022, 9(9), 477; https://doi.org/10.3390/bioengineering9090477 - 15 Sep 2022
Cited by 2 | Viewed by 3317
Abstract
The clustered regularly interspaced palindromic repeat (CRISPR)-Cas system has revolutionized genetic engineering due to its simplicity, stability, and precision since its discovery. This technology is utilized in a variety of fields, from basic research in medicine and biology to medical diagnosis and treatment, [...] Read more.
The clustered regularly interspaced palindromic repeat (CRISPR)-Cas system has revolutionized genetic engineering due to its simplicity, stability, and precision since its discovery. This technology is utilized in a variety of fields, from basic research in medicine and biology to medical diagnosis and treatment, and its potential is unbounded as new methods are developed. The review focused on medical applications and discussed the most recent treatment trends and limitations, with an emphasis on CRISPR-based therapeutics for infectious disease, oncology, and genetic disease, as well as CRISPR-based diagnostics, screening, immunotherapy, and cell therapy. Given its promising results, the successful implementation of the CRISPR-Cas system in clinical practice will require further investigation into its therapeutic applications. Full article
(This article belongs to the Special Issue Gene Engineering in Stem Cells for Drug Discovery and Therapeutic)
Show Figures

Graphical abstract

Back to TopTop